Equity Overview
Price & Market Data
Price: $2.09
Daily Change: +$0.13 / 6.22%
Daily Range: $2.00 - $2.19
Market Cap: $129,627,136
Daily Volume: 277,157
Performance Metrics
1 Week: 5.94%
1 Month: 8.08%
3 Months: 53.96%
6 Months: 94.55%
1 Year: -0.47%
YTD: 22.29%
Company Details
Employees: 61
Sector: Health technology
Industry: Pharmaceuticals: major
Country:
Details
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate Sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2, which has completed the INTERCEPT-AD phase 1 clinical trial and in ALTITUDE-AD phase 2 clinical trial to target soluble amyloid-beta oligomers. It has a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of Sabirnetug. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Newton, Massachusetts.